A
DvERSE drug events are an important medical safety concern in geriatric patients (1) . Polypharmacy and inappropriate prescribing are common in nursing home residents and increase the risk of adverse drug events and hospitalization (2) (3) (4) . A suggested approach to improve drug safety is to reduce the use of anticholinergic drugs (5) . These drugs are considered inappropriate in aged people due to their potentially negative effect on cognitive function (5, 6) . Still, anticholinergics are frequently prescribed to older adults, particularly in hospitals and nursing homes (7, 8) .
Anticholinergic side effects are caused by unselective antagonism of muscarinic receptor subtypes giving symptoms like urinary retention, constipation, mouth dryness, memory deficits, and falls (8, 9) . These symptoms may be misinterpreted as consequences of aging, and subsequently lead to prescription of symptom-relieving drugs rather than adjustment of the responsible drug(s). Many commonly prescribed medications have shown affinity to muscarinic receptors in vitro and may display anticholinergic activity (AA) in vivo (10) . High levels of serum anticholinergic activity (SAA) have been associated with increased risk of cognitive impairment in several observational studies in the elderly population (6, 11, 12) . However, the clinical impact of reducing the anticholinergic burden is still unknown, and there is a need for randomized controlled trials to assess the effects of decreased anticholinergic polypharmacy upon relevant symptoms of adverse drug events (13) .
Prevention of drug-related problems could benefit from a multidisciplinary approach. Clinical pharmacists have been reported to identify a large amount of drug-related problems that were solved in the multidisciplinary health care teams (14, 15) , but the effect of pharmaceutical interventions on relevant patient-oriented end points is largely unexplored. The objective of this study was to investigate if reduced anticholinergic drug burden-facilitated by pharmacist interventions-could improve cognitive function in nursing home residents.
Methods

Study Design and Participants
The Pharmacist-initiated Reduction of Anticholinergic Drug Activity study was a Norwegian, multicenter, randomized, single-blinded trial with one intervention group and one control group. The study was a repeated measures study that recruited long-term nursing home residents with a total anticholinergic drug scale (ADS) score of greater than or equal to 3 from 22 nursing homes during 11 months in 2008-2009. The ADS sum scores were determined after drug regimen assessments performed by a trained research nurse (author I.K.T.) or a clinical pharmacist (author H.K.). The ADS score model used was published by Carnahan et al. (16) in 2006. Each drug was categorized into four categories (0-3), where score 0 = no known AA and score 3 = markedly anticholinergic. We modified the AA ranking of some drugs according to a more recent in vitro study by Chew et al. (10) from 2008, where AA of 107 drugs were screened at therapeutic doses. The most recent study detected AA of some drugs not present in the original ADS and these were therefore added in the modified ADS model used in this study (10) .
Prior to inclusion, a local caregiver was consulted regarding the patients' physical and mental eligibility to participate in the study. Patients with blindness, deafness, aphasia, delirium, or severe dementia (score 3 on the Clinical Dementia Rating scale (17) , were excluded. The Regional Committee for Medical Research Ethics, the Norwegian Directorate of Health, and the Data Protection Officer at Oslo University Hospital approved the study protocol. Before randomization, written informed consent was obtained from the patients assessed as eligible for inclusion. For patients with reduced capacity to assent, their closest relative provided assumed consent.
Randomization
To account for possible differences in drug prescription practices between the centers, we conducted a stratified randomization where each nursing home represented one stratum. An independent research coordinator randomly allocated eligible patients within each stratum in a 1:1 manner to control or intervention group. The size of the strata varied from 2 to 15 patients with a median of 4.
Intervention-Drug Reviews
The intervention was based on a multidisciplinary drug review within 3 days after the baseline assessment. For patients randomized to the intervention group, the clinical pharmacist performed drug reviews guided by the ADS score model to advice the respective nursing home physician whether to discontinue or replace an anticholinergic drug with a drug alternative with less or no AA. When drug alternatives were unavailable, reduction in dosage was attempted to reduce the anticholinergic burden, but dose reductions did not affect the patients' overall ADS score. For ethical reasons, similar drug reviews were conducted for the control group after the last follow-up.
Data Collection and Measurements
The study nurse or the clinical pharmacist reviewed the included participants' medical records to obtain information about sociodemographic and clinical characteristics such as age, gender, education level, smoking habits, dental prostheses, diagnoses, serum creatinine, and use of regular drugs. The patients' morbidity was assessed by the Charlson Co-morbidity Index (18) , whereas the glomerular filtration rate was estimated using the Modification of Diet in Renal Disease (MDRD) study equation (19) . The medical records were reviewed at baseline and changes in drug-prescription or adverse events were registered at both follow-ups. Blood was sampled and cognitive tests were repeated at 4-and 8-week follow-ups, whereas mouth dryness was remeasured only at 4 weeks after baseline. This study schedule was chosen to reduce the nursing home patients' burden associated to study participation. Moreover, the antimuscarinic respond in saliva flow was regarded to manifest more rapidly and presumably within 4 weeks, whereas the central effects are related to more complex pharmacodynamics and pharmacokinetic mechanisms and 8 weeks was assumed necessary to restore central homeostatic control. The study nurse, who was masked for treatment allocation, carried out the baseline assessments and the retests 4 and 8 weeks following baseline.
Outcomes
Cognitive function.-The primary outcome was the patients' immediate free recall of words, from the Consortium to Establish a Registry for Alzheimer's Disease 10-wordlist (20) . Ten unrelated words were shown and read out to the patients and were asked to immediately recall as many words as possible. The wordlist was repeated twice and the maximum score was 30. New words were used at the retests. Secondary cognitive outcomes were Consortium to Establish a Registry for Alzheimer's Disease 10-wordlist test for delayed recall and recognition. In these two tests, the participants were asked to recall as many words as possible after 5 minutes, and to recognize the same 10 words from a list of 20 words. The Norwegian version of the global cognitive test Mini-Mental Sate Examination (21) was the final cognitive secondary outcome.
Mouth dryness.-Mouth dryness was included as a peripheral anticholinergic end point. The saliva flow was measured by a swab technique, placing two preweighted dental cotton rolls in the patients' lower jowl for 3 minutes and then in the upper vestibules at the opening of the parotid gland ducts for 3 minutes. The weight difference of the cotton rolls was used to determine the salivary flow (22) . The saliva flow was only remeasured at 4 weeks follow-up.
Serum Anticholinergic Activity.-Blood was sampled at baseline and after 4 and 8 weeks following intervention for the determination of SAA. Measurements were performed using a modified version of the radio receptor assay published by Tune and Coyle (23) in 1980. The modified anticholinergic assay has previously been published and described in detail (24) .
Statistics
As the intervention of this study, that is, removal of anticholinergic agents, could be viewed as an attempt to stimulate cholinergic activity, we applied the effect size defined as clinically relevant in studies with acetylcholine esterase inhibitors (30% improvement in immediate recall) when calculating study power. Assuming a mean baseline score of 15 ± 5 words in the study population, we therefore defined an improvement of five words in Consortium to Establish a Registry for Alzheimer's Diseases immediate recall test to be a clinically relevant effect size of the intervention. In order to show this effect with 95% statistical power and 5% significance level, a study sample of 60 participants was estimated to be required. To account for an expected dropout rate of 20% and missing data due to uncompleted tests, target recruitment was set to 100 patients.
The distribution of the variables was investigated graphically, and the residuals of the cognitive outcome variables were shown to be independent and normally distributed. A log transformation was conducted for SAA and saliva flow to attain normal distribution. We inspected the distribution of missing data between the study groups to identify the reasons for dropping out. As the dropouts did not seem to be related to the intervention, the primary analysis of the experimental effect was performed without imputed data (in per-protocol analyses), whereas secondary analyses were carried out by imputing the missing data by last observation carried forward.
Analyses of covariance were conducted to determine the difference in mean score from baseline to follow-ups between the intervention group and the control group, adjusted for baseline differences between the two groups. Secondarily, we adjusted for the stratum (nursing home) in the analyses of covariance. The primary analysis of the effect on Consortium to Establish a Registry for Alzheimer's Disease was performed at a significance level of 5%, whereas the secondary analyses were performed on a 1% significance level to reduce the risk of false positive findings due to multiple significance tests. Strictly, the primary outcome variable could be considered as a count variable (range 0-30 words). Therefore, a Poisson regression analysis was conducted as a supplementary analysis of the interventional effect. Finally, we carried out sensitivity analyses by parametric and nonparametric tests within and between the study groups on untransformed variables. IBM SPSS version 19 was used for all the statistical analyses.
Results
Of the 1,101 long-term nursing home residents who had their medications reviewed, 230 (21%) had an overall ADS score of greater than or equal to 3. Among these, 101 residents from 21 of the nursing homes were assessed to be eligible for randomization (Figure 1 ). Due to dropouts between randomization and the baseline assessment (n = 14), the number of patients available for participation was reduced to 87. Another 19 patients (22%) were lost by the 8th week. Overall, we lost 14 in the intervention group and 19 in the control group. Lack of motivation and unexpected events like infections were the main reasons behind the dropouts. The descriptive variables were well balanced between the intervention group and the control group (Table 1) . The participants had a mean age of 85 years and used in median 9 scheduled drugs with a median ADS score of 4. Table 2 shows the distribution of the total ADS scores at baseline and at 4-and 8-week follow-ups in both study groups. After 8 weeks, the median ADS score was significantly reduced from 4 to 2 in the intervention group, whereas it remained unchanged in the control group (p < .0001). The significant reduction in ADS score was achieved by replacement or withdrawal of anticholinergic drugs. The most frequently used anticholinergic drug was furosemide (score 1). Furosemide was used by 27 participants (31%) at baseline and was replaced by bumetanide in five patients. Hydroxyzine, the most frequently prescribed drug with an ADS score of 3, was used by 13 residents at baseline and was withdrawn 7 times, whereas urinary antimuscarinic agents (tolterodine and solifenacin) were discontinued from 6 medical regimens. In the intervention group (n = 40), 25 patients had their ADS score reduced by greater than or equal to 2 ADS units, 6 patients had their ADS score reduced to 0, whereas 18 patients still had an ADS score of greater than or equal to 3 at 8 weeks follow-up. Table 3 provides pre-and post-interventional per-protocol measures of the end points, whereas Figure 2 includes completed cases in immediate recall, saliva production, and SAA between baseline and follow-ups at each assessment. No statistically significant difference between the means was detected in any of the cognitive tests after 8 weeks (p > .19). Adjusting for nursing homes did not influence the results. The interventional effect on the primary outcome after adjusting for nursing home was 0.61 words, p = .42. Both study groups improved significantly in immediate and delayed recall from baseline to 8 weeks follow-up (p < .01). The largest improvement in immediate recall after 8 weeks was observed in the five patients in the intervention group who had their ADS score reduced to 0 (mean, +2.40 words; SD, 4.39). The remaining patients in the intervention group (n = 32) showed an improvement of 1.97 (±3.24) words in Secondary analyses estimating the effect of the intervention on the primary outcome by imputing the missing data (19 cases) by last observation carried forward, or by Poisson regression, did not alter the nonsignificant result obtained in the primary analysis.
With regard to peripheral anticholinergic end points, the saliva flow or SAA did not differ significantly between the subgroups at the follow-ups, that is, at 4 weeks (p = .34) and 8 weeks (p = .83), respectively. Moreover, there were no significant differences within the subgroups in the peripheral measures from baseline to 4 or 8 weeks follow-up (p > .13).
Discussion
To our knowledge, the Pharmacist-initiated Reduction of Anticholinergic Drug Activity study is the first randomized, controlled-intervention trial investigating the effect of reduced anticholinergic burden on peripheral and central clinical symptoms associated to AA in the elderly population. The intervention resulted in a significant reduction of the ADS score, but this did not translate into significant improvements of cognitive function or peripheral anticholinergic symptoms compared with the control group.
The pharmaceutical interventions significantly reduced the median ADS score with two units, whereas the score remained unchanged in the control group. In light of previous cross-sectional studies showing a significant association between ADS score and cognitive function (12, 25, 26) , the lack of cognitive improvement in the intervention compared with the control group was somewhat unexpected. However, characteristics of the study population might explain the lack of an interventional effect, for example, severe multimorbidity and high degree of cognitive impairments at baseline. Almost 70% of the included patients had mild-to-moderate dementia, and patients with less prominent pathological cholinergic dysfunction might be more sensitive toward a reduction in ADS score than those Notes: ADS = anticholinergic drug scale; CERAD = Consortium to Establish a Registry for Alzheimer Disease; SAA = serum anticholinergic activity. Percentages are of valid data in each group, n (%).
included in this study. This hypothesis is in line with three observational studies reporting no association between anticholinergic burden and cognitive functions in patients with dementia (27) (28) (29) . A possible pharmacological explanation for the lack of effect in this study is that a longer observation time might be required to regain the dynamics in cholinergic brain transmission after drug changes. It has been reported that cognitive dysfunction has improved 1-4 years after withdrawal of anticholinergic drugs (26, 30) . As anticholinergic drugs are reported to particularly interfere with the acquisition phase of memory processing, a short-time memory task was chosen as end point (31) . Other cognitive indicators like executive and psychomotor functions have also been related to anticholinergic drug use (26, 32, 33) . Thus, use of another cognitive end point might possibly have provided another outcome of the intervention. Our negative findings might also be explained by the relatively small sample size and the low inclusion rate, reflecting the low adherence that was expected in the current trial due to the inclusion of very old study participants and the real-life conditions (34) . Although the number of completed cases was above the calculated sample size (n = 60) needed to reach the a priori statistical power, the power analyses was based upon a population with less cognitive impairments than observed in our nursing home population (20) . Hence, our definition of improvement might have been too strict for power estimation, and despite that no significant differences were demonstrated in any of the cognitive tests, we cannot rule out that the intervention could have had a moderate effect.
In accordance with many previous observational studies, we quantified anticholinergic burden by summation of each drugs' ADS score (range 0-4 [12, 13, 25, 26, 35] ). There is no available consensus on how to define the drugs or exposures in the previously published anticholinergic scales, and the ADS used have several limitations, that is, dose intensity and brain distribution of the drugs are not assessed (34) The fact that SAA and mouth dryness, as peripheral anticholinergic end points, did not differ between the study groups at follow-up, further support that the ADS score model has serious limitations as an interventional tool for symptom improvement in clinical practice. Using an anticholinergic risk scale score that calculates anticholinergic burden from a continuously dose-weighted scale could be considered in future studies (36) .
Only five patients had their ADS score reduced to zero in the intervention group. These patients had the greatest observed improvement in cognitive symptoms. Thus, one might speculate that a total withdrawal of anticholinergic agents is required to obtain significant improvements on cognitive symptoms. This is supported by observational studies comparing the risk of anticholinergic side effects between patients with high and zero ADS score (12, (37) (38) (39) . Thus, it would have been interesting to perform a study intending to reduce the ADS score to zero.
We observed a significant increase in immediate and delayed recall in both study arms from baseline to 8 weeks follow-up. This improvement might indicate that the patients learned from the repetition of the test situation, but some improvements in the control group could have come from "leaking" of the intervention into the control patients in the same nursing homes. However, no reduction of the anticholinergic drug use was seen in the control group.
Multidisciplinary discussions including a clinical pharmacist provided a significant reduction in the use of anticholinergic drugs. Despite no effect on patient-related end points, this illustrates that the participation of clinical pharmacists in multidisciplinary health care teams might be effective for improving quality and safety of drug therapy in the elderly population.
A strength of our study is that all the tests were performed by the same study nurse who was blinded to group allocation. The internal validity is further strengthened by the consistency of the results across unadjusted and adjusted models of primary and secondary cognitive effect variables and in vitro and in vivo peripheral measures. The external validity is strengthened by the wide inclusion criteria ensuring a study population reflecting the variability in older adults.
To be clinically relevant, use of prescribing appropriateness tools must translate into positive patient outcomes, such as reduced rates of adverse drug events (40) . This study showed no significant improvement in cognitive function of the significant reduction in ADS score in nursing home residents. Neither did the reduction in ADS reduce SAA nor improve mouth dryness. This might indicate a limited applicability of the ADS score model as a prescription tool to reduce risk of anticholinergic adverse events in frail elderly patients in residential care. Pre-and post-interventional medians, interquartile ranges, and ranges (10th-90th percentiles) of observed cases during the study schedule in immediate recall, saliva flow, and serum anticholinergic activity (SAA) for the two study groups. The saliva flow was only measured at baseline and after 4 weeks. 
